Authors: Maura Pugliatti1,2, Hans-Peter Hartung3,4,5, Celia Oreja-Guevara6,7, Carlo Pozzilli8, Laura Airas9,10, Mona Alkhawajah11,12, Nikolaos Grigoriadis13, Melinda Magyari14, Bart Van Wijmeersch15,16,17, Magd Zakaria18, Ralf Linker19, Andrew Chan20, Patrick Vermersch21 and Thomas Berger22,23
1Department of Neuroscience and Rehabilitation, University of Ferrara, Ferrara, Italy, 2Interdepartmental Center of Research for Multiple Sclerosis and Neuro-inflammatory and Degenerative Diseases, University of Ferrara, Ferrara, Italy, 3Department of Neurology, Medical Faculty, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany, 4Brain and Mind Center, University of Sydney, Sydney, NSW, Australia, 5Department of Neurology, Palacky University Olomouc, Olomouc, Czechia, 6Department of Neurology, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain, 7Faculty of Medicine, Complutense University of Madrid (UCM), Madrid, Spain, 8Multiple Sclerosis Center, S. Andrea Hospital, Department of Human Neuroscience, University Sapienza, Rome, Italy, 9Division of Clinical Neurosciences, University of Turku, Turku, Finland, 10Neurocenter of Turku University Hospital, Turku, Finland, 11Section of Neurology, Neurosciences Center, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia, 12College of Medicine, Al Faisal University, Riyadh, Saudi Arabia, 13Laboratory of Experimental Neurology and Neuroimmunology, Second Department of Neurology, American Hellenic Educational Progressive Association (AHEPA) University Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece, 14Danish Multiple Sclerosis Center, Department of Neurology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, 15Universitair Multiple Sclerosis (MS) Centrum, Hasselt-Pelt, Belgium, 16Revalidatie & Multiple Sclerosis (MS), Noorderhart, Pelt, Belgium, 17Rehabilitation Research Center (REVAL) & Biomedical Research Institute (BIOMED), Hasselt University, Hasselt, Belgium, 18Department of Neurology, Ain Shams University, Cairo, Egypt, 19Clinic and Polyclinic for Neurology, Universitätsklinikum Regensburg, Regensburg, Germany, 20Department of Neurology, Inselspital Bern, Bern University Hospital, University of Bern, Bern, Switzerland, 21University of Lille, Inserm U1172 LilNCog, CHU Lille, FHU Precise, Lille, France, 22Department of Neurology, Medical University of Vienna, Vienna, Austria, 23Comprehensive Center for Clinical Neurosciences and Mental Health, Medical University of Vienna, Vienna, Austria
It has been over a year since people with multiple sclerosis (pwMS) have been receiving vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). With a negligible number of cases in which vaccination led to a relapse or new onset MS, experts around the world agree that the potential consequences of COVID-19 in pwMS by far outweigh the risks of vaccination. This article reviews the currently available types of anti-SARS-CoV-2 vaccines and the immune responses they elicit in pwMS treated with different DMTs. Findings to date highlight the importance of vaccine timing in relation to DMT dosing to maximize protection, and of encouraging pwMS to get booster doses when offered.
© 2022 Pugliatti, Hartung, Oreja-Guevara, Pozzilli, Airas, Alkhawajah, Grigoriadis, Magyari, Van Wijmeersch, Zakaria, Linker, Chan, Vermersch and Berger.
Author(s)Prof Maura Pugliatti, Prof Hans-Peter Hartung, Prof Celia Oreja-Guevara, Prof Carlo Pozzilli, Prof Laura Airas, Prof Mona Alkhawajah, Prof Nikolaos Grigoriadis, Prof Melinda Magyari, Prof Bart Van Wijmeersch, Prof Magd Zakaria, Prof Ralf Linker, Prof Andrew Chan, Prof Patrick Vermersch, Prof Thomas Berger
Release DateOctober 17, 2022